Employees: 11-50
Portfolio 13
| Date | Name | Website | Total Raised | Location |
| - | Shanghai Y... | yl-pharma.com | - | - |
| - | Pykus Ther... | pykustherapeutics.com | - | - |
| - | Circle Pha... | circlepharma.com | $207.5M | United Sta... |
| - | Camp4 | camp4tx.com | $175M | United Sta... |
| - | Obsidian T... | obsidiantx.com | $325.04M | United Sta... |
| - | blueoakpharma.com | - | - | |
| - | APRINOIA T... | aprinoia.com | $11M | Taiwan, Ta... |
| - | Morphic Th... | morphictx.com | $131.5M | United Sta... |
| - | Tilos Ther... | tilostherapeutics.com | - | - |
| - | Valitor | valitorbio.com | $28M | United Sta... |
Show more
News 21
| Date | Title | Description |
| - | ShangPharma Innovation Names Two Executives-In-Residence | SOUTH SAN FRANCISCO, Calif., Oct. 24, 2017 – ShangPharma Innovation Inc., a global venture capital firm and innovation incubator focused on biomedical R&D therapeutics and technologies, announced the appointment of Dirk G. Brockstedt, P... |
| - | ShangPharma Innovation Appoints Mohamad Moghadam-Tabrizi as Senior Vice President of Business Development | ShangPharma Innovation (SPI) today announced the appointment of Mohamad Moghadam-Tabrizi to the position of Senior Vice President, Business Development. Mr. Tabrizi previously served in senior and executive level positions in corporate bus... |
| - | ShangPharma Innovation portfolio company Tilos Therapeutics acquired for up to $773 Million by Merck | KENILWORTH, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it has entered into a definitive agreement to acquire Tilos Therapeutics, a privately held biopharmaceutical company... |
| - | Endpoints: When VCs hand out mega-rounds to Vir and Gossamer, are they betting on the jockey or the horse? | “Following a period of unprecedented returns for biopharma investors, flush VCs are sinking bigger and bigger rounds of cash into companies whose pipelines are still in their infancy. Taking this trend to a new level is an increasingly popu... |
| - | ShangPharma Innovation and SRI International Announce Drug Discovery Collaboration | Strategic partnership to target Alzheimer’s disease and other neurodegenerative and inflammatory conditions MENLO PARK, Calif., October 9, 2017 – ShangPharma Innovation Inc. (SPII) and SRI International today announced a strategic collabor... |
| - | BioWorld: Other news to note | “Shangpharma Innovation Inc., of South San Francisco, inked a multiyear strategic collaboration with the Icahn School of Medicine at Mount Sinai designed to accelerate the development of early stage therapeutics, including validation of dru... |
| - | New York Business Journal: ShangPharma Innovation partners with Icahn School of Medicine | “Venture capital firm ShangPharma Innovation Inc. is teaming up with the Icahn School of Medicine at Mount Sinai (ISMMS) to accelerate the development of early-stage therapeutics. As part of the multi-year strategic collaboration, ShangPha... |
| - | ShangPharma Innovation and the University of California San Francisco Announce Strategic Research Collaboration | — New innovation group and leading medical center partner on novel approach to advance therapies across the often overlooked early-stage gap in biomedical research — SOUTH SAN FRANCISCO and SAN FRANCISCO, Calif., July 11, 2017 – In a new c... |
| - | ShangPharma Innovation and Icahn School of Medicine at Mount Sinai Forge Translational Research Collaboration | SOUTH SAN FRANCISCO, California and NEW YORK, Jan. 16, 2017 — ShangPharma Innovation Inc., a global venture capital firm focused on biomedical R&D therapeutics and technologies, and Icahn School of Medicine at Mount Sinai (ISMMS) have e... |
| - | Partners HealthCare raises $171 million to invest in early-stage life science companies | Boston, Massachusetts., Nov. 8, 2017 – Exclusively dedicated to the development of breakthrough technologies that help patients and the state’s innovation economy. Partners HealthCare System announced today the closing of $171.1 million in... |
Show more
Mentions in press and media 4
| Date | Title | Description |
| 06.11.2019 | Artios Pharma, MD Anderson and ShangPharma Announce In-Licensing Agreement for DNA Damage Response Inhibitor | CAMBRIDGE, England and HOUSTON and SOUTH SAN FRANCISCO, Calif., Nov. 6, 2019 — Artios Pharma Limited (Artios), The University of Texas MD Anderson Cancer Center (MD Anderson) and ShangPharma Innovation (ShangPharma) today announce the in-li... |
| 19.03.2018 | ShangPharma boosts Bay Area reach for early-stage research | Venture capital firm ShangPharma Innovation is growing its life science incubator on the West Coast as it looks to help early-stage biomedical work get off the ground with more lab space. Sponsored by Agilent Technologies How would you like... |
| 19.03.2018 | ShangPharma boosts Bay Area reach for early-stage research | Venture capital firm ShangPharma Innovation is growing its life science incubator on the West Coast as it looks to help early-stage biomedical work get off the ground with more lab space. The firm, which also provides access to its resident... |
| 27.10.2017 | ShangPharma Innovation Appoints Two Executives-In-Residence | ShangPharma Innovation Inc., a South San Francisco, CA-based global venture capital firm and innovation incubator focused on biomedical R&D therapeutics and technologies, has appointed Dirk G. Brockstedt, Ph.D., and Benson Tsang, MBA, t... |